CORRESP 1 filename1.htm

 

 

140 Scott Drive

 

Menlo Park, California 94025

 

Tel: +1.650.328.4600 Fax: +1.650.463.2600

 

www.lw.com

 

 

FIRM / AFFILIATE OFFICES

Barcelona

Moscow

 

Beijing

Munich

 

Boston

New York

 

Brussels

Orange County

 

Century City

Paris

 

Chicago

Riyadh

Corvus Pharmaceuticals, Inc.

Dubai

Rome

863 Mitten Road, Suite 102

Düsseldorf

San Diego

Burlingame, CA 94010

Frankfurt

San Francisco

 

Hamburg

Seoul

 

Hong Kong

Shanghai

June 7, 2017

Houston

Silicon Valley

 

London

Singapore

 

Los Angeles

Tokyo

 

Madrid

Washington, D.C.

 

Milan

 

 

VIA EDGAR TRANSMISSION

 

Johnny Gharib, General Attorney

Division of Corporation Finance

Office of Healthcare and Insurance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

Re:                             Corvus Pharmaceuticals, Inc.

Registration Statement on Form S-3

Initially Filed April 3, 2017 and Amended May 26, 2017

File No. 333-217102

 

Dear Mr. Gharib:

 

In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Corvus Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date of the above-referenced Registration Statement be accelerated so that the Registration Statement will become effective under the Securities Act on June 9, 2017 at 4:00 p.m. Eastern Daylight Time, or as soon thereafter as practicable.  We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of such Registration Statement be sent to our counsel, Latham & Watkins LLP, Attention: Kathleen M. Wells, by facsimile to (650) 463-2600.

 

In connection with this request, the Company acknowledges that:

 

·                  should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

 



 

Corvus Pharmaceuticals, Inc.

Page 2

 

 

·                  the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 

·                  the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

The cooperation of the staff in meeting our request is very much appreciated.  If you have any questions or comments, please contact Kathleen M. Wells of Latham & Watkins LLP at (650) 463-2677 or kathleen.wells@lw.com.  Thank you for your assistance with these matters.

 

 

Very truly yours,

 

CORVUS PHARMACEUTICALS, INC.

 

 

 

 

 

/s/ Leiv Lea

 

Leiv Lea

 

Chief Financial Officer

 

cc:                                Alan C. Mendelson, Esq. of Latham & Watkins LLP

Kathleen M. Wells, Esq. of Latham & Watkins LLP